FDA issues marketing approval for APP Pharmaceuticals' Penicillin G potassium for Injection, USP

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ: APCVZ), announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market penicillin G potassium for Injection, USP, in two dosage strengths. Penicillin G is therapeutically equivalent to the reference drug PfizerPen™ G, which is marketed by the innovator Pfizer, Inc.

APP will package Penicillin G in 5 million and 20 million unit single dose vials. APP's Penicillin G is AP-rated, bar-coded and latex-free. According to IMS data, 2008 sales of this product in the United States were approximately $16.4 million1.

Penicillin G is used to treat a wide variety of bacterial infections, including pneumococcal infections, streptococcal infections, staphylococcal infections, diphtheria, meningitis, clostridial infections and anthrax. According to the Centers for Disease Control and Prevention (CDC), Penicillin G is the treatment of choice for congenital syphilis, neurosyphilis and prophylaxis of intrapartum group B streptococcus.

“The addition of Penicillin G further strengthens APP’s broad anti-infective portfolio,” said Thomas H. Silberg, president and chief executive officer of APP Pharmaceuticals. “We are looking forward to making this potentially life-saving antibiotic available to patients throughout the U.S.”


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Researchers develop new nanoparticle that efficiently and selectively kills cancer cells